Pyrazole P38 MAP Kinase Inhibitors Isoform Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p38 MAP kinase inhibitors face challenges due to toxicity and lack of specificity, particularly for p38 MAPK gamma and delta isoforms, which limits their therapeutic potential in treating chronic inflammatory diseases like COPD and severe asthma.
Innovation Solution
Development of a compound of formula (I) that selectively inhibits p38 MAP kinase, specifically targeting certain sub-types with improved anti-inflammatory effects and reduced toxicity, allowing for enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If pan-isoform p38 MAPK inhibitors are used, then broad inhibition coverage is achieved, but toxicity increases due to ubiquitous expression of alpha and beta isoforms
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features (aromatic substituents at defined positions, heteroatom placement) that confer selective binding affinity for gamma and delta isoforms while reducing affinity for alpha and beta isoforms. This structural differentiation enables the inhibitor to target specific tissue locations where gamma/delta isoforms are expressed without affecting ubiquitously expressed alpha/beta isoforms, thereby reducing systemic toxicity.
Solution Approach 2:
The patent segments the p38 MAPK inhibition function by creating compounds that selectively inhibit specific isoforms (gamma and delta) rather than all isoforms. This segmentation is achieved through careful design of the core pyrazole structure with specific substituent patterns that match the unique binding pockets of gamma/delta isoforms, separating the inhibition function from pan-isoform activity.
2Object-affected harmful factors
If selective inhibitors for gamma and delta isoforms are developed, then toxicity is reduced, but currently no such selective compounds are available
Solution Approach 1:
The patent applies parameter changes by systematically varying key molecular parameters of the pyrazole core structure, including substituent types (aromatic, heteroatom-containing), substituent positions (2, 4, 5 positions), and linker characteristics. These parameter variations were optimized to achieve the critical threshold of selectivity for gamma/delta isoforms while maintaining adequate potency, transforming the compound properties from non-selective to selectively inhibitory.
3Reliability
If earlier generation p38 MAPK inhibitors are used, then inhibition potency is achieved, but off-target effects increase leading to high toxicity
Solution Approach 1:
The patent applies local quality by introducing specific structural features at defined locations on the pyrazole core (aromatic substituents at 2, 4, 5 positions with specific heteroatom content) that enhance binding affinity for the target isoform's active site while reducing interaction with off-target proteins. This localized structural optimization maintains potent inhibition of the intended target while minimizing off-target effects.
Data Source
AI summary
There are provided inter alia compounds of formula (I)wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.